Manus Biosynthesis is a technology company.
Manus Biosynthesis has raised $75.0M across 1 funding round.
Manus Biosynthesis has raised $75.0M in total across 1 funding round.
Manus Biosynthesis has raised $75.0M in total across 1 funding round.
Manus Biosynthesis's investors include Ethos Family Office.
Manus Biosynthesis (Manus Bio) is a technology company specializing in synthetic biology to produce complex natural ingredients through microbial fermentation. Their platform recreates plant biochemical processes in microorganisms to manufacture rare and expensive ingredients used in flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio’s core mission is to accelerate the transition from traditional, resource-intensive sourcing methods to sustainable, bio-based alternatives ("bioalternatives") by enabling scalable, cost-effective production at industrial scale. Their technology addresses the challenge of commercializing complex molecules by bridging the gap between lab discovery and manufacturing scale, thus supporting companies across industries in adopting sustainable bioingredients[1][2][4][5].
Founded out of MIT by Dr. Aji Parayil, Dr. Greg Stephanopoulos, and a team of biochemical engineers, Manus Bio emerged from decades of metabolic engineering research pioneered by Dr. Stephanopoulos. The founders recognized the opportunity to industrialize and scale the production of complex, plant-based natural products using engineered microbial cell factories. The company was built on the principle that scaling biocatalysts efficiently is essential to realizing synthetic biology’s promise. Early traction came from successfully commercializing multiple bioingredients and bio-sweeteners, demonstrating their ability to overcome the "Valley of Death" between lab innovation and commercial manufacturing[1].
Manus Bio rides the growing global trend toward sustainable biomanufacturing and synthetic biology as solutions to environmental challenges and resource constraints. With the world’s population projected to increase significantly by 2050, traditional agricultural expansion is limited, creating urgent demand for alternative ingredient sources. Manus Bio’s microbial fermentation platform addresses this by enabling scalable production of natural products without the environmental footprint of farming or petrochemical extraction. This positions them at the forefront of the bioeconomy, influencing the broader ecosystem by accelerating adoption of bioalternatives that support sustainability, cost reduction, and supply chain resilience[4][5].
Looking ahead, Manus Bio is poised to expand its impact by scaling more bioingredients and entering new markets, driven by increasing corporate and consumer demand for sustainable products. Advances in synthetic biology, automation, and bioprocessing will likely enhance their platform’s efficiency and product diversity. Their collaborative model with industry leaders will continue to facilitate commercialization and market penetration. As sustainability and bioinnovation become central to global supply chains, Manus Bio’s role as a scale-up enabler will grow, potentially reshaping how natural ingredients are sourced worldwide and contributing significantly to the bio-based economy[1][5].
In summary, Manus Biosynthesis exemplifies the transition from traditional chemical and agricultural sourcing to scalable, sustainable bioalternatives, leveraging cutting-edge synthetic biology to meet future global needs.
Manus Biosynthesis has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $75.0M Series B | Ethos Family Office |